Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands

OBJECTIVE: To assess the cost effectiveness of cetuximab in third-line treatment of patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC) in routine clinical practice compared with best supportive care (BSC). METHODS: Patients (n = 287) with KRAS wt mCRC treated with cetuximab or BSC...

Descripción completa

Detalles Bibliográficos
Autores principales: Uyl-de Groot, Carin A., van Rooijen, Elisabeth M., Punt, Cornelis J. A., Pescott, Chris P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6049844/
https://www.ncbi.nlm.nih.gov/pubmed/30019286
http://dx.doi.org/10.1186/s13561-018-0197-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6049844/
https://www.ncbi.nlm.nih.gov/pubmed/30019286
http://dx.doi.org/10.1186/s13561-018-0197-3

Ejemplares similares